Imunon, Inc. (IMNN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory

Original reporting
Published Aug 11, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

This is primarily a governance and compensation disclosure. It can marginally affect dilution expectations and investor perception of equity usage, but it does not indicate a new capital raise or change in business strategy.

02

Market read

Traders may monitor the scheduled share issuance/election dates for any short-term supply overhang, but the filing lacks new financial or strategic catalysts.

03

What to watch

Traders may focus on the specific election windows and pay dates (Aug 14, Aug 28 to Sep 25, 2026) as potential timing for incremental share supply, even without a new financing announcement.

Relevance 6/10Novelty 4/10Timing: filed Aug 11, 2026 after-hours (8-K)

Background

The company filed an SEC Form 8-K under Item 5.02 describing compensatory arrangements for certain executive officers, allowing base salary to be paid in common stock and granting additional shares tied to elections.

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon disclosed an 8-K Item 5.02 approving stock-based compensatory programs for CEO, Executive Chairman, and CMO.

Expected impact

Low likelihood of a sustained move; any reaction is likely muted and short-lived unless paired with other corporate developments.

Evidence & confidence

The disclosure specifies percentages of base salary payable in shares and additional share issuance schedules, but provides no new operating guidance, financing, or strategic transaction.

Market effects

Minimal spillover; executive equity compensation is common across small-cap biotech and typically does not reset sector expectations.

None.

None.

Counterpoint

If the share issuance elections imply higher near-term dilution than investors assumed, the stock could see a brief negative reaction despite the filing being standard compensation mechanics.

Key entities

  • Imunon, Inc.

    Nasdaq-listed company filing the 8-K describing executive stock-based compensation elections and additional share issuance.

  • Stacy Lindborg

    President and CEO, eligible for up to 50% of base salary in shares and additional shares under the program.

  • Michael Tardugno

    Executive Chairman, eligible for up to 100% of base salary in shares and additional shares under the program.

  • Douglas Faller

    Chief Medical Officer, eligible for up to 40% of base salary in shares and additional shares under the program.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.